Reportable, Inc.: Anticancer Bioscience Presenting at Biotech Showcase Digital 2021 Showcasing its Synthetic Lethal Precision Oncology Pipeline for the First Time To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
Anticancer Bioscience is participating in Biotech Showcase Digital 2021.
The Company will showcase its pioneering approach to precision oncology, and how it is applying its synthetic lethality expertise for better cancer therapies.
The Company has five distinct synthetic lethality programs in drug development.
Click image above to view full announcement. About Anticancer Bioscience - https://www.anticancerbio.com/ Anticancer Bioscience (ACB) is an international private company, commercialising discoveries emerging from China s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. Pioneers in synthetic lethal approaches to precision oncology and experts in MYC
Registration: https://informaconnect.com/biotech-showcase/registration-options/
During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme s pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company s flagship product, DuraGraft
, an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase
During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme s pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company s flagship product, DuraGraft
®, an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase
Börse Express - Marizyme, Inc. wird während der J.P. Morgan Healthcare Conference Biotech Showcase Digital an der Biotech Showcase 2021 und während der "J.P. Morgan Week 2021" an der BIO @ JPM teilnehmen boerse-express.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-express.com Daily Mail and Mail on Sunday newspapers.
Marizyme, Inc. wird während der J.P. Morgan Healthcare Conference Biotech Showcase Digital an der Biotech Showcase 2021 und während der "J.P. Morgan Week 2021" an der BIO @ JPM teilnehmen prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.